CVR Medical Appoints Dr. Paul S. Blunden to Medical Board of Directors
October 20, 2016 – Vancouver, British Columbia (TSX-V: CVM) CVR Medical Corp. (“CVR Medical”) has appointed Dr. Paul S. Blunden to its Board of Directors. From this position, Dr. Blunden will serve in interpretive and advisory capacities as CVR Medical moves toward market launch.
Certified since 1992 by the American Board of Obstetrics & Gynaecology, Dr. Blunden has worked in private practice and holds privileges with several of the most reputable hospitals in Southeast Michigan. With over two decades of executive experience, and as one of the original members of the CVR Global team, his understanding of the clinical value and application for this technology will continue to provide a foundation of leadership and stability. CVR Medical and CVR Global are grateful for his contributions and excited to announce this new position.
In speaking of his appointment, Dr. Blunden states, “Having been involved in this process from the beginning, I believe that CVR Medical and CVR Global have incredible foresight that will bring great benefit to the world, and I look forward to being a part of that.”
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com.
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company’s control. These forwardlooking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.